Prothena’s Mission Is to Make a Real Impact for Patients
We are pioneering protein dysregulation science to create a better future for people with neurodegenerative and rare peripheral amyloid diseases who are in critical need of new treatment options.
Our diversified portfolio is designed to make a significant impact on rare peripheral amyloid and neurodegenerative diseases.
Our Biology-Directed Engine Propels Prothena’s Progress Across Our Broad Pipeline
Prothena’s Biology-Directed Engine combines comprehensive and methodical identification of the optimal targeting regions on pathogenic proteins, and development of drugs that mitigate the effects of these proteins, while leaving the normal, healthy protein structure and function intact.
This scientific approach has translated into clinical proof of concept on endpoints that are meaningful to patients across a number of programs and continues to advance novel therapeutics that specifically target the forms of proteins that cause disease.
Please visit our Pipeline page for Prothena’s complete R&D Pipeline.